A UK-based trial is investigating whether metformin, a diabetes drug, and atomoxetine, an ADHD medication, can slow the progression of Alzheimer’s disease. The study, led by a team at a UK research institution, aims to evaluate the potential of these two medications to reduce cognitive decline in patients with Alzheimer’s or dementia.
Participants will be elderly individuals diagnosed with Alzheimer’s or dementia, with a focus on those in early stages of the condition. The trial will involve a six-month period during which participants will receive either the combination of metformin and atomoxetine or a placebo. Researchers will monitor cognitive function, memory retention, and overall disease progression using standardized assessments.
This trial follows growing interest in repurposing existing drugs for neurodegenerative conditions. Previous studies have suggested that metformin may have neuroprotective properties, while atomoxetine has shown potential in improving attention and reducing inflammation. The UK research team hopes to provide new evidence on whether these medications could offer a non-invasive, cost-effective treatment option for Alzheimer’s. The results are expected to be published in a peer-reviewed journal by early 2025.
